



Three Sugar Creek Center, Suite 300
Sugar Land, TX 77478

SA-22621B1
Physicians of East Texas
Betsy Wagner
111 B Gaslight Blvd
Lufkin, TX 75904-3190



Important information for your office

107

As published in the June 1, 2020, edition of Aetna OfficeLink Updates™



Changes to our National Precertification List (NPL)

Important NPL update

Effective **September 1, 2020**, the following precertification changes apply:

- We'll require precertification for the following drugs:
 - Eligard® (leuprolide acetate)
 - Firmagon® (degarelix)
 - Lupron Depot® (leuprolide acetate)
 - Rituxan Hycela® (rituximab/hyaluronidase human)
 - Sandostatin® LAR (octreotide acetate)
 - Signifor® (pasireotide)
 - Somavert® (pegvisomant)
 - Trelstar® (triptorelin pamoate)
 - Zoladex® (goserelin acetate)
- We'll require precertification for both the drug and site of care for the following drugs:
 - Cinqair® (reslizumab)
 - Fasenra® (benralizumab)
 - Nucala® (mepolizumab)
 - Xolair® (omalizumab)

The following new-to-market drugs require precertification:

- Ziextenzo® (pegfilgrastim-bmez) — precertification required, effective February 1, 2020.
This drug is included in the granulocyte colony-stimulating factor category.



- Adakveo® (crizanlizumab-tmca) — precertification for both the drug and site of care required, effective February 13, 2020.
- Reblozyl® (luspaterecept-ãamt) — precertification required, effective February 13, 2020.
- Asceniv™ (immune globulin intravenous, human — slra) — precertification for both the drug and site of care required, effective March 1, 2020.
- Vyondys 53® (golodirsen) — precertification for both the drug and site of care required, effective March 10, 2020.
- Enhertu® (fam-trastuzumab deruxtecan-nxki) — precertification required, effective March 24, 2020. This drug is included in the HER2 receptor targeted drug category.
- Padcev™ (enfortumab vedotin-ejfv) — precertification required, effective March 24, 2020.
- Bonsity™ (teriparatide) — precertification required, effective May 1, 2020. This drug is included in the osteoporosis drug category.

Effective **April 1, 2020**, the following new-to-market drugs will require precertification:

- Esperoct® (antihemophilic factor [recombinant], glycopegylated-exei)
- Ogivri™ (trastuzumab-dkst)
- Ruxience™ (rituximab-pvvr)
- Trazimera™ (trastuzumab-qyyp)
- Vumerity™ (diroximel fumarate)

We encourage you to submit precertification requests at least two weeks before the scheduled services.

To save time, request precertification electronically — it's fast and simple. Most precertification requests can be submitted electronically through the provider website or by using your Electronic Medical Record (EMR) system portal.

You can find more information about precertification under the "General Information" section of the [NPL](#).

Changes to commercial drug lists begin on October 1, 2020

On **October 1**, we'll update our pharmacy drug lists.

You'll be able to view the changes as early as August 1. They'll be available then on our [Formularies & Pharmacy Clinical Policy Bulletins](#) page.

Ways to request a drug prior authorization

- Submit your completed request form through our [provider website](#).
- Fax your completed [prior authorization request form](#) to 1-877-269-9916.

- If you have a request for a nonspecialty drug, call the Aetna Pharmacy Precertification Unit at **1-855-240-0535 (TTY: 711)**.
- If you have a request for a drug on the Aetna Specialty Drug List, call the Aetna Pharmacy Precertification Unit at **1-866-814-5506**.

These changes will affect all Pharmacy Management drug lists, precertification, quantity limits and step-therapy programs.

For more information, call the Aetna Pharmacy Management Provider Help Line at **1-800-238-6279 (1-800-AETNA RX) (TTY: 711)**.

Allowable non-emergent basic life support transport services

Non-Emergent Basic Life Support Ground Ambulance Transport Services, identified by HCPC A0428, will only be allowed when it's the only way to safely and adequately transport the patient and when other means of transport are unsafe due to the medical condition of the patient.

Examples of when we'll allow the non-emergent basic life support code A0428 are when the patient:

- Has a bed confinement status
- Needs continuous supervision
- Has other reduced mobility
- Requires physical restraint
- Is dependent on enabling machines and devices
- Is being transported from one hospital to another or from a hospital to a skilled nursing facility and back

As of **September 1, 2020**, we will no longer cover any non-emergent basic life support transport service for routine care, patient convenience or non-emergency reasons, unless a prior authorization is submitted and approved.

Claim editing enhancements for medical specialty pharmacy

Beginning **September 1, 2020**, we'll enhance our daily unit-limit claim editing for medical specialty drugs for our Medicare members. We'll use a phased approach, and we'll apply diagnostic and member characteristics (age, diagnosis, gender, etc.) to determine the specialty



drugs' quantity limits. You may see temporary differences in this population's claims adjudication across the Medicare Advantage programs.

This enhancement is a part of the new Novologix® online prior authorization system. We began applying this editing to our commercial members on March 1, 2020.

Accurate claims processing with our Third Party Claim and Code Review Program

Beginning **September 1, 2020**, you may see new claims edits. These are part of our Third Party Claim and Code Review Program. These edits support our continuing effort to process claims accurately. You can view these edits on our provider website. We will also begin to apply Third Party Claim and Code Review Program edits to Medicare claims in a phased approach.

You'll have access to our prospective claims editing disclosure tool. To find out if our new claims edits will apply to your claim, log in to the provider website. Then, go to Aetna Payer Space > Resources > Expanded claim edits. You'll need to know your Aetna Provider ID Number (PIN).

Note: This is subject to regulatory review and separate notification in Washington state.

Note to all providers, including Coventry providers: To view the June 2020 OfficeLink Updates (OLU) online and link to all information in this flyer, go to [aetna.com](https://www.aetna.com). Click on "Providers," then under "Resources & reports," click on "Newsletters & news." Remember, OLU comes out in March, June, September and December.

Aetna is the brand name used for products and services provided by one or more of the Aetna group of subsidiary companies, including Aetna Life Insurance Company and its affiliates (Aetna).

This material is for informational purposes only and contains only a partial, general description of plan benefits or programs and does not constitute a contract. Aetna arranges for the provision of health care services. While this material is believed to be accurate as of the print date, it is subject to change.

The information and/or programs described in this newsletter may not necessarily apply to all services in this region. Contact your Aetna® network representative to find out what is available in your local network. Application of copayments and/or coinsurance may vary by plan design. This newsletter is provided solely for your information and is not intended as legal advice. If you have any questions concerning the application or interpretation of any law mentioned in this newsletter, please contact your attorney.

[aetna.com](https://www.aetna.com)

©2020 Aetna Inc.

83.03.866.1 (06/20)